Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide

It is indicated for the treatment of well differentiated GEP-NETs
28 Jul 2017
Endocrine and neuroendocrine tumours

On 20 July 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product lutetium (177Lu) oxodotreotide (Lutathera), a radiopharmaceutical medicinal product indicated for the treatment of well differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

It was designated as an orphan medicinal product on 31 January 2008.

The applicant for this medicinal product is Advanced Accelerator Applications.

It will be available as a 370 MBq/ml solution for infusion.

The active substance of Lutathera is lutetium (177Lu) oxodotreotide, a radiolabelled peptide that has high affinity for subtype 2 somatostatin receptors (sst2) (ATC code: V10XX04). It targets malignant cells which overexpress sst2 receptors and has a limited effect on neighbouring noncancerous cells.

The benefits with lutetium (177Lu) oxodotreotide are its ability to improve progression-free survival compared with octreotide LAR, a somatostatin receptor agonist, in patients with well differentiated GEP-NET tumours.

The most common side effects are nausea, vomiting, haematological toxicity (thrombocytopenia, lymphopenia, anaemia, pancytopenia), fatigue and decreased appetite.

The full indication is:

"Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults."

It should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings and after evaluation of the patient by a qualified physician.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 28 Jul 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.